Revvity Signals Banner Ad (Nov-Dec)

EDITORIAL SECTION

KNOWLEDGE BANK

  • Techno Trends

    Lilly’s Jaypirca Gains FDA Approval for First-Line CLL/SLL Treatment

    Eli Lilly and Company has received approval from the US Food and Drug Administration FDA for an additional indication for Jaypirca pirtobrutinib in adults with previously untreated chronic lymphocytic leukaemia CLL or small lymphocytic lymphoma SLL without a known p deletion The approval enables Jaypirca to be used as a firstline treatment

TOP ARTICLES

  • 4

    Quality in Pharmaceutical Manufacturing

    Venkata Reddy Pothireddy

    Quality is fundamental to pharmaceutical manufacturing, ensuring product safety, efficacy, consistency, and regulatory compliance. This review discusses pharmaceutical quality principles, Quality Mana...

  • 5

    Patient-Centric Approaches in Clinical Trials

    Vasudev Bhupathi

    Patient-centric clinical trials embed participants’ needs at every stage, co-designed protocols, decentralized visits, digital health tools, diversity metrics, and transparent results. This para...

press releasesRead more...

Stipple Bio Announces Multi-Target Multi-Modality Oncology Research Collaboration with Lilly

Stipple Bio Inc a private biotechnology company harnessing epitopelevel precision to create targeted cancer therapies today announced that it has entered into a multitarget multimodality strategic research collaboration and license agreement with Eli Lilly and Company

Cardiff Oncology Receives FDA Fast Track Designation for Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer

Cardiff Oncology Inc Nasdaq CRDF a clinicalstage biotechnology company targeting RASmutated cancer by leveraging PLK inhibition today announced that the US Food and Drug Administration FDA has granted Fast Track designation to onvansertib in combination

Sino Biological Launches 4RISE™ High-Throughput Wet-Lab Services to Accelerate AI-Driven Drug Discovery

AIdriven protein design is accelerating the discovery of novel protein binders but experimental validation remains essential to determine whether computational designs translate into meaningful target interactions To bridge this gap Sino Biological Inc Shenzhen Stock Exchange SZ a global leader in r...

Kamau Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Nula-cel, a Gene-Corrected Stem Cell Therapy for Sickle Cell Disease

Kamau Therapeutics a clinicalstage company creating medicines that endure by precisely engineering patients own blood stem cells today announced that the US Food and Drug Administration FDA has granted Regenerative Medicine

24 - 27

Nov 2026

Pharmtech & Ingredients 2026

Crocus Expo, Pavilion 2, Mosco...

24 - 25

Nov 2026

BioPharma Deals Conference 2026

Science Congress Center, Munic...

26 - 28

Nov 2026

One Health Conference 2026

Thapar Institute of Engineerin...

01 - 03

Dec 2026

Pharmaceutical Launch Excellence Summit

Novotel Amsterdam City, Nether...

01 - 03

Dec 2026

10th Antifibrotic Drug Development

Boston, MA at the Hotel Common...

02 - 04

Dec 2026

Genome Informatics 2026

Wellcome Genome Campus, UK

03 - 04

Dec 2026

LATEST NEWSRead more...

Novartis’ Cosentyx becomes first anti-IL-17 biologic approved for polymyalgia rheumatica

Novartis has received approval from the US Food and Drug Administration FDA for Cosentyx secukinumab mg to treat adults with polymyalgia rheumatica PMR who have not responded adequately to corticosteroids or cannot tolerate a reduction in their corticosteroid dose

Roche’s Gazyva/Gazyvaro becomes first FDA-approved treatment for primary membranous nephropathy

Roche has received approval from the US Food and Drug Administration FDA for GazyvaGazyvaro obinutuzumab to treat adults with primary membranous nephropathy pMN who are at risk of disease progression

Cyclarity Therapeutics Receives FDA Clearance for UDP-003 Clinical Trial Application in the US

Cyclarity Therapeutics Inc has received clearance from the US Food and Drug Administration FDA for its Investigational New Drug IND application for UDP enabling the company to expand its atherosclerosis clinical development programme into the United States

Santhera Signs Distribution Agreement with SteinCares for AGAMREE in 31 Latin American and Caribbean Countries

Cyclarity Therapeutics Inc has received clearance from the US Food and Drug Administration FDA for its Investigational New Drug IND application for UDP enabling the company to expand its atherosclerosis clinical development programme into the United States

Oncolytics Biotech Signs Clinical Supply Agreement to Evaluate Pelareorep with LOQTORZI in Anal Cancer

Oncolytics Biotech Inc Nasdaq ONCY a clinicalstage immunotherapy company developing pelareorep has signed a clinical supply agreement with Coherus Oncology to evaluate pelareorep in combination with LOQTORZI toripalimabtpzi in patients with squamous cell anal carcinoma SCAC

MD Logic Health and Blu Vitals Launch Nine-Form Magnesium Supplement Mag 9+

MD Logic Health has partnered with Blu Vitals to launch Mag the first product developed through their collaboration The new magnesium supplement combines nine forms of magnesium with four additional nutrients in a daily formula designed to support energy production muscle and nerve function and bon...